There’s a famous quote by Friedrich Nietzsche that says “That which does not kill us makes us stronger.” I have follicular ...

Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.

Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has reported promising results from its Phase Ib/IIa clinical trial of IMM0306, a bispecific molecule for treating indolent lymphoma. The trial ...

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through new clinical data from the ...

Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a “watch-and ...

Santa Monica, California Thursday, November 7, 2024, 10:00 Hrs [IST] ...